2021
Quantifying publication rates and time to publication for urologic oncology podium presentations.
Mikhail M, Chua K, Patel H, Tabakin A, Doppalapudi S, Ghodoussipour S, Kim I, Jang T, Srivastava A, Singer E. Quantifying publication rates and time to publication for urologic oncology podium presentations. Journal Of Clinical Oncology 2021, 39: 357-357. DOI: 10.1200/jco.2021.39.6_suppl.357.Peer-Reviewed Original ResearchPodium presentationsAmerican Urological Association annual meetingsFull-length manuscriptsPeer-reviewed journalsMedian timeBladder cancerProstate cancerUrologic oncologyMedian journal impact factorPublication rateAnnual MeetingPresentationCancerPresentation abstractsAUA meetingMatching publicationsMeeting attendanceManuscript publicationConclusionAUA Annual MeetingJournal impact factorUnpublished researchAssociation Annual MeetingTrends in the use of administrative databases in urologic oncology: 2000 – 2019.
Leopold Z, Dave P, Menon A, Patel H, Srivastava A, Kim I, Jang T, Singer E. Trends in the use of administrative databases in urologic oncology: 2000 – 2019. Journal Of Clinical Oncology 2021, 39: 356-356. DOI: 10.1200/jco.2021.39.6_suppl.356.Peer-Reviewed Original ResearchNational Surgical Quality Improvement ProgramPremier Healthcare DatabaseNational Cancer DatabaseNationwide Inpatient SampleAdministrative databasesUrologic oncologySEER-MedicareSurgical Quality Improvement ProgramStudy periodEnd Results (SEER) databaseQuality Improvement ProgramRepresentative study populationComparative effectiveness researchResults databaseGenitourinary malignanciesInpatient SampleBladder cancerCancer DatabaseProstate cancerInclusion criteriaStudy populationTreatment trendsAD useHealthcare databasesLarger sample sizeTrends in the use of administrative databases in urologic oncology: 2000–2019
Leopold Z, Dave P, Menon A, Patel H, Srivastava A, Kim I, Jang T, Singer E. Trends in the use of administrative databases in urologic oncology: 2000–2019. Urologic Oncology Seminars And Original Investigations 2021, 39: 487-492. PMID: 33551250, DOI: 10.1016/j.urolonc.2021.01.014.Peer-Reviewed Original ResearchConceptsAdministrative databasesUrologic oncologyNational Surgical Quality Improvement ProgramSurgical Quality Improvement ProgramPremier Healthcare DatabaseEnd Results (SEER) databaseNational Cancer DatabaseNationwide Inpatient SampleQuality Improvement ProgramRepresentative study populationComparative effectiveness researchGenitourinary malignanciesResults databaseSEER-MedicareInpatient SampleBladder cancerCancer DatabaseProstate cancerInclusion criteriaStudy populationTreatment trendsAD useHealthcare databasesLarger sample sizeStudy period
2019
A novel tumor suppressing gene, ARHGAP9, is an independent prognostic biomarker for bladder cancer
Piao X, Jeong P, Yan C, Kim Y, Byun Y, Xu Y, Kang H, Seo S, Kim W, Lee J, Kim I, Moon S, Choi Y, Cha E, Yun S, Kim W. A novel tumor suppressing gene, ARHGAP9, is an independent prognostic biomarker for bladder cancer. Oncology Letters 2019, 19: 476-486. PMID: 31897161, PMCID: PMC6924059, DOI: 10.3892/ol.2019.11123.Peer-Reviewed Original ResearchNon-muscle invasive BCMuscle-invasive BCIndependent prognostic biomarkerInvasive BCPrognostic biomarkerProlonged recurrence-free survivalCancer-specific survivalCancer-specific deathRecurrence-free survivalTissues of patientsBC tissue samplesExpression of mRNAVital clinical significanceMIBC patientsBC prognosisPoor prognosisBladder cancerClinical significanceCancer tumorigenesisUseful markerLow expressionPatientsNovel tumorHigh expressionTissue samplesUrinary Cell-Free DNA IQGAP3/BMP4 Ratio as a Prognostic Marker for Non–Muscle-Invasive Bladder Cancer
Xu Y, Kim Y, Jeong P, Piao X, Byun Y, Seo S, Kang H, Kim W, Lee J, Ryu D, Choi J, Kim I, Moon S, Choi Y, Yun S, Kim W. Urinary Cell-Free DNA IQGAP3/BMP4 Ratio as a Prognostic Marker for Non–Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer 2019, 17: e704-e711. PMID: 31088707, DOI: 10.1016/j.clgc.2019.04.001.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBiomarkers, TumorBone Morphogenetic Protein 4Cell-Free Nucleic AcidsDisease ProgressionFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGenes, Tumor SuppressorGTPase-Activating ProteinsHumansMaleMiddle AgedNuclear ProteinsPrognosisSurvival AnalysisUrinary Bladder NeoplasmsConceptsProgression-free survivalCox regression analysisRecurrence-free survivalDisease recurrenceBladder cancerNon-muscle invasive bladder cancerInvasive bladder cancer patientsWorse progression-free survivalMultivariate Cox regression analysisWorse recurrence-free survivalKaplan-Meier analysisKaplan-Meier curvesBladder cancer patientsRegression analysisUrinary cell-free DNAValuable novel biomarkersCell-free DNANMIBC patientsClinical outcomesCancer patientsDisease progressionPrognostic markerReal-time PCRNovel biomarkersIndependent factors
2018
Diagnostic value of combined IQGAP3/BMP4 and IQGAP3/FAM107A expression ratios in urinary cell-free DNA for discriminating bladder cancer from hematuria
Xu Y, Kim Y, Jeong P, Piao X, Byun Y, Kang H, Kim W, Lee J, Kim I, Moon S, Choi Y, Yun S, Kim W. Diagnostic value of combined IQGAP3/BMP4 and IQGAP3/FAM107A expression ratios in urinary cell-free DNA for discriminating bladder cancer from hematuria. Urologic Oncology Seminars And Original Investigations 2018, 37: 86-96. PMID: 30446454, DOI: 10.1016/j.urolonc.2018.10.023.Peer-Reviewed Original ResearchConceptsBladder cancerUrinary cell-free DNACell-free DNAScreening groupHematuria patientsValidation cohortPredictive valueUrine-based markersNegative predictive valuePositive predictive valueGood diagnostic performanceStudy cohortBC patientsUrological cancersNoninvasive biomarkersPatientsScore indexDiagnostic valueHematuriaExpression level ratioLiquid biopsyCohortDiagnostic performanceCancerDS-indexRole of the androgen signaling axis in genitourinary malignancies.
Shinder B, Shupe A, Lee G, Stein M, Kim I, Singer E. Role of the androgen signaling axis in genitourinary malignancies. Translational Cancer Research 2018, 7: 1135-1142. PMID: 30701159, PMCID: PMC6349041, DOI: 10.21037/tcr.2018.03.41.Peer-Reviewed Original ResearchRenal cell carcinomaGenitourinary malignanciesAndrogen receptorBladder cancerRole of ARAdvanced disease stateProstate cancer developmentNovel therapeutic strategiesCell carcinomaTherapeutic armamentariumTherapeutic strategiesMortality rateCancer developmentMalignancyAndrogensDisease statesCancerCarcinomaProstateArmamentariumMolecular biologyDiseaseProgressionRoleReceptorsThe Anticancer Effects of Garlic Extracts on Bladder Cancer Compared to Cisplatin: A Common Mechanism of Action via Centromere Protein M
Kim W, Seo S, Byun Y, Kang H, Kim Y, Lee S, Jeong P, Song H, Choe S, Kim D, Kim S, Ha Y, Moon S, Lee G, Kim I, Yun S, Kim W. The Anticancer Effects of Garlic Extracts on Bladder Cancer Compared to Cisplatin: A Common Mechanism of Action via Centromere Protein M. The American Journal Of Chinese Medicine 2018, 46: 689-705. PMID: 29595070, DOI: 10.1142/s0192415x18500362.Peer-Reviewed Original ResearchConceptsCentromere protein MBladder cancerBC patientsGarlic extractBetter progression-free survivalNude mouse xenograft modelProgression-free survivalCisplatin-treated miceBALB/cTissue microarray analysisNegative control miceMouse xenograft modelBC cell linesEffect of garlicMicroarray analysisCisplatin groupControl miceTumor weightControl tumorsTumor volumeNormal controlsXenograft modelSide effectsBody weightTumor tissue
2017
Garlic extract in bladder cancer prevention: Evidence from T24 bladder cancer cell xenograft model, tissue microarray, and gene network analysis
Kim W, Seo S, Byun Y, Kang H, Kim Y, Lee S, Jeong P, Seo Y, Choe S, Kim D, Kim S, Moon S, Choi Y, Lee G, Kim I, Yun S, Kim W. Garlic extract in bladder cancer prevention: Evidence from T24 bladder cancer cell xenograft model, tissue microarray, and gene network analysis. International Journal Of Oncology 2017, 51: 204-212. PMID: 28498422, DOI: 10.3892/ijo.2017.3993.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsApoptosisBiomarkers, TumorCell ProliferationGarlicGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansMaleMiceMice, Inbred BALB CMice, NudePlant ExtractsSignal TransductionTissue Array AnalysisTumor Cells, CulturedUrinary Bladder NeoplasmsXenograft Model Antitumor AssaysConceptsCancer preventionBladder cancerGarlic extractXenograft modelNude mouse xenograft modelAcceptable safety profileBladder cancer preventionCancer prevention activitiesCell xenograft modelBALB/cTissue microarray analysisMouse xenograft modelMicroarray analysisTumor weightBC patientsSafety profileTumor volumeTissue microarrayControl groupGene network analysisControl dietPrevention activitiesPreventionExtract intakePotential mechanisms
2014
Diagnosis of bladder cancer and prediction of survival by urinary metabolomics
Jin X, Yun S, Jeong P, Kim I, Kim W, Park S. Diagnosis of bladder cancer and prediction of survival by urinary metabolomics. Oncotarget 2014, 5: 1635-1645. PMID: 24721970, PMCID: PMC4039236, DOI: 10.18632/oncotarget.1744.Peer-Reviewed Original ResearchConceptsBladder cancerControl groupCancer groupCancer-specific survival timeMuscle-invasive bladder cancerInvasive bladder cancerMetabolomic profilesPrediction of survivalHigh-performance liquid chromatography-quadrupole timeLiquid chromatography-quadrupole timeUrinary metabolomicsCommon cancerControl subjectsUrinary cytologyBC diagnosisDiagnostic modalitiesSurvival timeCurrent modalitiesUrine metabolitesMetabolomics-based approachPatientsCancerDifferential metabolitesClinical applicabilityCarnitine transferaseThe predictive value of polymorphisms in predicting the early response to induction BCG therapy in patients with non–muscle invasive bladder cancer
Kang H, Tchey D, Yan C, Kim W, Kim Y, Yun S, Lee S, Choi Y, Kim I, Kim W. The predictive value of polymorphisms in predicting the early response to induction BCG therapy in patients with non–muscle invasive bladder cancer. Urologic Oncology Seminars And Original Investigations 2014, 32: 458-465. PMID: 24411789, DOI: 10.1016/j.urolonc.2013.10.013.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBCG VaccineCarcinoma, Transitional CellFemaleFollow-Up StudiesGenotypeGlutathione TransferaseHumansMaleMiddle AgedNeoplasm GradingNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPolymerase Chain ReactionPolymorphism, GeneticPrognosisRisk FactorsSmokingSurvival RateUrinary Bladder NeoplasmsConceptsNon-muscle invasive bladder cancerGSTT1-positive genotypeInvasive bladder cancerPrimary non-muscle invasive bladder cancerBCG failureBladder cancerPredictive valueInduction therapyIndependent predictorsHigh riskBacillus Calmette-Guérin induction therapyNull genotypeMultivariate logistic regression analysisMultivariate logistic regression modelBCG induction therapyInduction BCG therapySingle induction courseDisease-free survivalGlutathione S-transferase muKaplan-Meier analysisHigh-risk groupKaplan-Meier estimatesEarly responseLogistic regression analysisGSTT1 null genotype
2013
Decreased DBC1 Expression Is Associated With Poor Prognosis in Patients With Non-Muscle-Invasive Bladder Cancer
Shim U, Lee I, Kang H, Kim J, Kim W, Kim I, Ryu K, Choi Y, Moon S, Kim Y, Yun S, Lee S, Kim W. Decreased DBC1 Expression Is Associated With Poor Prognosis in Patients With Non-Muscle-Invasive Bladder Cancer. Investigative And Clinical Urology 2013, 54: 631-637. PMID: 24044099, PMCID: PMC3773595, DOI: 10.4111/kju.2013.54.9.631.Peer-Reviewed Original ResearchBladder cancerDBC1 expressionExpression of DBC1Prognostic valuePrognostic markerNon-muscle invasive bladder cancerMultivariate Cox regression analysisMultivariate Cox regression modelCancer-specific survivalCox regression analysisKaplan-Meier analysisPredictors of progressionCox regression modelKaplan-Meier estimatesUseful prognostic markerAggressive tumor characteristicsNormal bladder mucosaPolymerase chain reaction analysisTumor characteristicsPoor prognosisTumor recurrenceReal-time polymerase chain reaction analysisBladder mucosaClinicopathologic parametersNMIBCHOXA9, ISL1 and ALDH1A3 methylation patterns as prognostic markers for nonmuscle invasive bladder cancer: Array‐based DNA methylation and expression profiling
Kim Y, Yoon H, Kim J, Kang H, Min B, Kim S, Ha Y, Kim I, Ryu K, Lee S, Kim W. HOXA9, ISL1 and ALDH1A3 methylation patterns as prognostic markers for nonmuscle invasive bladder cancer: Array‐based DNA methylation and expression profiling. International Journal Of Cancer 2013, 133: 1135-1142. PMID: 23436614, DOI: 10.1002/ijc.28121.Peer-Reviewed Original ResearchConceptsISL LIM homeobox 1Novel methylation markersDNA methylationNonmuscle invasive bladder cancerMethylation patternsHomeobox A9DNA methylation patternsInvasive bladder cancerDecreased gene expression levelsLIM homeobox 1RNA expression patternsGene expression profilesAldehyde dehydrogenase 1 familyGene expression levelsMethylation markersNMIBC patientsDisease recurrenceBladder cancerExpression profilingExpression patternsExpression profilesMicroarray analysisNormal controlsPyrosequencing analysisHomeobox 1
2012
Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer
YUN S, JEONG P, KIM W, KIM T, LEE Y, SONG P, CHOI Y, KIM I, MOON S, KIM W. Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer. International Journal Of Oncology 2012, 41: 1871-1878. PMID: 22961325, DOI: 10.3892/ijo.2012.1622.Peer-Reviewed Original ResearchConceptsBladder cancerCell-free miRNAsMiR-200aMiR-145Transitional cell carcinomaBladder cancer patientsNon-cancer controlsHealthy normal controlsMiR-145 levelsMiR-200a levelsCell-free microRNAsNMIBC recurrenceIndependent predictorsClinicopathological featuresCell carcinomaCancer patientsPrognostic biomarkerUrinary bladderHigh riskNoninvasive biomarkersNormal controlsAccurate biomarkersMultivariate analysisPatientsCancerRUNX3 methylation in normal surrounding urothelium of patients with non-muscle-invasive bladder cancer: Potential role in the prediction of tumor progression
Jeong P, Min B, Ha Y, Song P, Kim I, Ryu K, Kim J, Yun S, Kim W. RUNX3 methylation in normal surrounding urothelium of patients with non-muscle-invasive bladder cancer: Potential role in the prediction of tumor progression. European Journal Of Surgical Oncology 2012, 38: 1095-1100. PMID: 22884471, DOI: 10.1016/j.ejso.2012.07.116.Peer-Reviewed Original ResearchConceptsNon-muscle invasive bladder cancerNormal adjacent urotheliumInvasive bladder cancerTransurethral resectionNormal urotheliumAdjacent urotheliumRUNX3 methylationRUNX3 promoter methylationNMIBC patientsBladder cancerTumor tissueMultivariate Cox regression analysisUrothelium of patientsCox regression analysisKaplan-Meier estimatesPromoter methylationBladder tumor developmentNormal adjacent tissuesMethylation-specific polymerase chain reactionIndependent predictorsTumor numberPolymerase chain reactionPatientsSignificant associationTumor progression396 TUMORIGENIC AND PROGNOSTIC SIGNIFICANCE OF RASSF1A EXPRESSION IN NON-MUSCLE-INVASIVE LOW-GRADE (WHO G1 AND G2) BLADDER CANCER
HA Y, KIM Y, KIM J, Lee S, KIM I, Kim W, Seo J, Kim W, Chae Y, Yun S. 396 TUMORIGENIC AND PROGNOSTIC SIGNIFICANCE OF RASSF1A EXPRESSION IN NON-MUSCLE-INVASIVE LOW-GRADE (WHO G1 AND G2) BLADDER CANCER. Journal Of Urology 2012, 187: e162. DOI: 10.1016/j.juro.2012.02.460.Peer-Reviewed Original ResearchTumorigenic and Prognostic Significance of RASSF1A Expression in Low-grade (WHO Grade 1 and Grade 2) Nonmuscle-invasive Bladder Cancer
Ha Y, Jeong P, Kim J, Kwon W, Kim I, Yun S, Kim G, Choi Y, Moon S, Kim W. Tumorigenic and Prognostic Significance of RASSF1A Expression in Low-grade (WHO Grade 1 and Grade 2) Nonmuscle-invasive Bladder Cancer. Urology 2012, 79: 1411.e1-1411.e6. PMID: 22446336, DOI: 10.1016/j.urology.2012.01.042.Peer-Reviewed Original ResearchConceptsLow-grade nonmuscle-invasive bladder cancersNonmuscle invasive bladder cancerPolymerase chain reactionBladder cancerTumor tissueMultivariate Cox regression analysisMRNA expressionTissue levelsRASSF1A expressionCox regression analysisKaplan-Meier estimatesChain reactionNormal bladder mucosaTumor tissue levelsNormal tissue levelsReal-time polymerase chain reactionRASSF1A promoter methylationQuantitative real-time polymerase chain reactionMethylation-specific polymerase chain reactionEffect of RASSF1AT ratioIndependent predictorsPrognostic significancePrognostic valueLarge tumorsRas Association Domain Family 1A: A Promising Prognostic Marker in Recurrent Nonmuscle Invasive Bladder Cancer
Kim J, Chae Y, Ha Y, Kim I, Byun S, Yun S, Kim W. Ras Association Domain Family 1A: A Promising Prognostic Marker in Recurrent Nonmuscle Invasive Bladder Cancer. Clinical Genitourinary Cancer 2012, 10: 114-120. PMID: 22382007, DOI: 10.1016/j.clgc.2011.12.003.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Transitional CellChildDNA MethylationFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPrognosisPromoter Regions, GeneticProportional Hazards ModelsTumor BurdenTumor Suppressor ProteinsUrinary Bladder NeoplasmsYoung AdultConceptsRecurrent nonmuscle invasive bladder cancerNonmuscle invasive bladder cancerMuscle-invasive bladder cancerInvasive bladder cancerPrimary BC tissuesCox regression analysisBladder cancerPrognostic markerRASSF1A methylationRASSF1A hypermethylationIndependent predictorsBC tissuesMultivariate Cox regression analysisCancer progressionKaplan-Meier analysisAdvanced tumor stagePromising prognostic markerPromoter hypermethylationPotential prognostic markerRegression analysisRASSF1A promoter hypermethylationMethylation-specific polymerase chain reactionClinicopathologic featuresPrognostic significanceKaplan-Meier
2011
Novel combination markers for predicting progression of nonmuscle invasive bladder cancer
Ha Y, Kim J, Yoon H, Jeong P, Kim T, Yun S, Lee S, Kim G, Choi Y, Moon S, Kim I, Kim W. Novel combination markers for predicting progression of nonmuscle invasive bladder cancer. International Journal Of Cancer 2011, 131: e501-e507. PMID: 22025348, DOI: 10.1002/ijc.27319.Peer-Reviewed Original ResearchConceptsNonmuscle invasive bladder cancerInvasive bladder cancerMethylation-specific polymerase chain reactionBladder cancerNMIBC progressionMultivariate Cox regression analysisPredictive combinationCox regression analysisKaplan-Meier estimatesMRNA expression levelsBest predictive combinationMedian followRUNX3 promoter methylationIntravesical therapyPrognostic effectSpecific polymerase chain reactionSubgroup analysisEffect of RUNX3Prognostic markerReal-time PCRHigh riskCombination markersPatientsMRNA expressionProgressionRUNX3 methylation as a predictor for disease progression in patients with non‐muscle‐invasive bladder cancer
Yan C, Kim Y, Ha Y, Kim I, Kim Y, Yun S, Moon S, Bae S, Kim W. RUNX3 methylation as a predictor for disease progression in patients with non‐muscle‐invasive bladder cancer. Journal Of Surgical Oncology 2011, 105: 425-430. PMID: 22311819, DOI: 10.1002/jso.22087.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overCarcinoma in SituCarcinoma, Transitional CellChildCore Binding Factor Alpha 3 SubunitDisease ProgressionDNA MethylationDNA, NeoplasmFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansLymphatic MetastasisMaleMiddle AgedNeoplasm GradingNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPolymerase Chain ReactionPrognosisPromoter Regions, GeneticSurvival RateUrinary Bladder NeoplasmsYoung AdultConceptsDisease progressionRUNX3 methylation statusRUNX3 methylationTumor stageBladder cancerTumor gradeNMIBC progressionInvasive bladder cancer patientsWorse progression-free survivalProgression-free survivalInvasive bladder cancerPoor clinical outcomeKaplan-Meier estimatesBladder cancer patientsMethylation statusNumber of tumorsHypermethylation of RUNX3Methylation-specific polymerase chain reactionNMIBC samplesAdvanced diseaseClinical outcomesClinicopathological characteristicsIndependent predictorsCancer patientsG3 tumors